PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
Superficial Basal Cell Carcinoma
DRUG: PEP005 (ingenol mebutate) Gel, 0.05%|DEVICE: Aluminium disk|DEVICE: OpSite(TM) disk
Treatment related Adverse Events, Local Skin Responses; Pigmentation and scarring, Number of participants with treatment related Adverse Events, change from baseline in LSR and pigmentation and scarring., 120 days
Histological and clinical clearance of sBCC lesions., Number of participants with histological and clinical clearance of sBCC lesions., 120 days
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.